24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet global health Ročník 13; číslo 2; s. e355 - e363
Hlavní autori:	Sweeney, Sedona, Laurence, Yoko V, Berry, Catherine, Singh, Maninder Pal, Dodd, Matthew, Fielding, Katherine, Kazounis, Emil, Moodliar, Ronelle, Solodovnikova, Varvara, Tigay, Zinaida, Liverko, Irina, Parpieva, Nargiza, Butabekov, Ilhomjon, Usmanova, Ruzilya, Rassool, Mohammed, Motta, Ilaria, Nyangweso, George Mokua, Jolivet, Pascal, Abdrasuliev, Tleubergen, Moe, Soe, Aw, Pei Sun, Samieva, Nazgul, Nyang'wa, Bern-Thomas
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.02.2025
Predmet:	Administration, Oral Adult Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Diarylquinolines - economics Diarylquinolines - therapeutic use Drug Therapy, Combination Female Humans Male Quality-Adjusted Life Years Rifampin - therapeutic use South Africa Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics Tuberculosis, Pulmonary - drug therapy South Africa
ISSN:	2214-109X, 2214-109X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!